SHL has announced it is exhibiting at the 2018 Drug Delivery Partnerships (DDP) conference in Florida.
Taking place from 22 January to 24 January, the company will present its innovative drug delivery devices and its commercialisation solutions for final assembly, labelling and packaging.
Manager of business development at SHL Pharma Jamie Gould said: 鈥淒DP鈥檚 an event that has for the past two decades been an important meeting place for drug delivery leaders.
鈥淲ith the increased use of biologic and biosimilar formulations to treat chronic indications, SHL鈥檚 safe and reliable self-injection offerings meet the industry鈥檚 demand for efficient drug delivery devices that are designed to improve treatment outcomes.鈥�
During the event, SHL will introduce the groundbreaking Maggie庐, a two-step cartridge-based auto-injector for high-volume injections built with SHL鈥檚 market-proven Needle Isolation Technology (NIT庐). Also on display is Bertha庐, a versatile auto-injector that can accommodate a wide range of fill volumes and viscosities.
SHL will also present its Molly庐 2.25 auto-injector, which is designed with the same robust features as the classic Molly庐 family of pre-configured devices. This high-volume variation is equally safe and intuitive, and offers the same flexibility and short development timelines for faster commercialisation.
To find out more about SHL鈥檚 latest innovations and comprehensive solutions for device commercialisation, visit Booth 301 at the PGA National Resort & Spa in Palm Beach Gardens, Florida.